These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24170548)

  • 1. Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
    Damaraju VL; Scriver T; Mowles D; Kuzma M; Ryan AJ; Cass CE; Sawyer MB
    Clin Cancer Res; 2014 Jan; 20(1):176-86. PubMed ID: 24170548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.
    Mackey JR; Yao SY; Smith KM; Karpinski E; Baldwin SA; Cass CE; Young JD
    J Natl Cancer Inst; 1999 Nov; 91(21):1876-81. PubMed ID: 10547395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.
    Damaraju VL; Smith KM; Mowles D; Nowak I; Karpinski E; Young JD; Robins MJ; Cass CE
    Biochem Pharmacol; 2011 Jan; 81(1):82-90. PubMed ID: 20854794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
    Damaraju VL; Kuzma M; Mowles D; Cass CE; Sawyer MB
    Mol Cancer Ther; 2015 Jan; 14(1):236-45. PubMed ID: 25519698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine.
    Clarke ML; Damaraju VL; Zhang J; Mowles D; Tackaberry T; Lang T; Smith KM; Young JD; Tomkinson B; Cass CE
    Mol Pharmacol; 2006 Jul; 70(1):303-10. PubMed ID: 16617163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
    García-Manteiga J; Molina-Arcas M; Casado FJ; Mazo A; Pastor-Anglada M
    Clin Cancer Res; 2003 Oct; 9(13):5000-8. PubMed ID: 14581375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.
    Damaraju VL; Mowles D; Yao S; Ng A; Young JD; Cass CE; Tong Z
    Nucleosides Nucleotides Nucleic Acids; 2012; 31(3):236-55. PubMed ID: 22356238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS.
    Damaraju VL; Weber D; Kuzma M; Cass CE; Sawyer MB
    J Biol Chem; 2016 Sep; 291(36):18809-17. PubMed ID: 27432881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside.
    Damaraju VL; Visser F; Zhang J; Mowles D; Ng AM; Young JD; Jayaram HN; Cass CE
    Mol Pharmacol; 2005 Jan; 67(1):273-9. PubMed ID: 15486050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
    Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
    Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney.
    Damaraju VL; Elwi AN; Hunter C; Carpenter P; Santos C; Barron GM; Sun X; Baldwin SA; Young JD; Mackey JR; Sawyer MB; Cass CE
    Am J Physiol Renal Physiol; 2007 Jul; 293(1):F200-11. PubMed ID: 17409283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
    Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.
    Govindarajan R; Endres CJ; Whittington D; LeCluyse E; Pastor-Anglada M; Tse CM; Unadkat JD
    Am J Physiol Gastrointest Liver Physiol; 2008 Sep; 295(3):G570-80. PubMed ID: 18635603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta.
    Govindarajan R; Bakken AH; Hudkins KL; Lai Y; Casado FJ; Pastor-Anglada M; Tse CM; Hayashi J; Unadkat JD
    Am J Physiol Regul Integr Comp Physiol; 2007 Nov; 293(5):R1809-22. PubMed ID: 17761511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
    Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
    Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake.
    Paproski RJ; Yao SY; Favis N; Evans D; Young JD; Cass CE; Zemp RJ
    PLoS One; 2013; 8(2):e56423. PubMed ID: 23441192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of 2',2'-difluorodeoxycytidine (gemcitabine) and formycin B with the Na+-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells.
    Burke T; Lee S; Ferguson PJ; Hammond JR
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1333-40. PubMed ID: 9732397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.